Novo Nordisk's Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
Eli Lilly and Co (LLY.US) Mounjaro has replaced Novo-Nordisk A/S (NVO.US) Wegovy as the new favorite weight loss drug in the United Kingdom.
The number of private individuals in the United Kingdom purchasing weight loss drugs is continuously increasing, with Eli Lilly and Co's Mounjaro gradually surpassing Novo-Nordisk A/S's Wegovy, becoming a new favorite among consumers.
Here's Why Novo Nordisk A/S (NVO) Fell in Q3
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Express News | European Medicines Agency's Committee For Medicinal Products For Human Use Adopted Positive Opinion For Update Of Novo Nordisk's Ozempic
